Educational information only. Not medical advice.
Compare compounds, understand the differences, and explore the original studies behind them.
Research reviewed October 15, 2026. Start with the overview, then explore the evidence and sources.
Stages summarize the study designs available for the identified material in this selection. Human stages require studies in which people received that material; measuring the body’s own peptide or testing a different analogue does not qualify. Controlled studies can measure hormone responses or other biological changes, as well as clinical outcomes. A higher stage can include unsuccessful trials; the adjacent summary explains the findings and limitations.
Multiple reports from one trial count as one study for this classification. The selected-report totals below describe library coverage. Outcome-specific certainty would require a separate assessment of study limitations, consistency, applicability, precision and publication bias.
CJC-1295 with DAC has a modified GHRH core plus an extra modified lysine carrying a reactive DAC group. That addition allows it to bind albumin, a blood protein, and helps prolong exposure.
Modified GRF(1–29) is a 29-amino-acid GHRH analogue with four substitutions and an amide at the end of the chain. It lacks the albumin-binding DAC group.
CJC-1295 with DAC has been studied for prolonged stimulation of growth hormone and insulin-like growth factor 1 (IGF-1), its downstream growth signal, in healthy adults. Animal work examined growth in mice missing a normal hormone-releasing signal. The human studies did not test improved strength, recovery or longevity.
Modified GRF(1–29) is examined in seized-product identification and anti-doping research to establish the DAC-free peptide's identity, breakdown products and laboratory detectability. Human hormone studies of CJC-1295 with DAC concern a different, albumin-binding preparation.
The categories describe the most advanced study designs selected for this library. Each summary explains what was measured and what remains uncertain.
Multiple controlled human studies
Two separate placebo-controlled healthy-adult trials found sustained increases in growth hormone and insulin-like growth factor 1 (IGF-1), its downstream growth signal, after the DAC-containing peptide. Their endpoints were circulating hormones, not physical function or disease prevention. Another small study measured overnight hormone pulses; its later protein-marker paper reused participants. These results do not establish benefits for strength or recovery.
Laboratory studies
The selected direct studies identify the DAC-free preparation and examine its breakdown and detection in laboratory samples. They do not administer it to patients. Human results for CJC-1295 with DAC, natural GRF(1–29) or a singly substituted analogue cannot establish the clinical effects or exposure of this exact modified fragment.
Both peptides are based on growth hormone-releasing hormone (GHRH), which signals the pituitary to release growth hormone. DAC is an added chemical group that allows CJC-1295 to attach to albumin, an abundant blood protein. Modified GRF(1–29) lacks this addition.
Has a modified GHRH sequence plus an extra modified lysine carrying the albumin-binding DAC group.
Has a 29-amino-acid GHRH sequence, substitutions at positions 2, 8, 15 and 27, and an amide at the end of the chain. It has no DAC group.
A human elimination half-life requires blood samples collected after administration of a defined peptide. It describes how long the measured concentration takes to fall by half during the elimination phase; it does not measure recovery from injury or another clinical benefit.
Trials in healthy adults who received injections under the skin reported an estimated half-life of 5.8–8.1 days. The tested peptide had DAC; its salt form was not specified.
The reviewed studies did not provide a measured human blood concentration profile or a reliable numerical half-life for this four-substitution peptide without DAC.
Growth hormone (GH) is released in pulses. Between pulses its concentration falls to a trough. GH also promotes production of insulin-like growth factor 1 (IGF-1), so the peptide concentration, GH pattern and IGF-1 response are related but different measurements.
Human trials found prolonged increases in GH and IGF-1. In a separate overnight sampling study, GH pulses remained similar in frequency and size, but concentrations between pulses and average GH concentrations increased.
The reviewed sources did not establish the corresponding human hormone response for this peptide. The DAC results used a different molecule and cannot supply those missing measurements.
Chemical identification studies test what a preparation contains. Laboratory detection studies can also add known peptides to urine to check whether an assay detects them. Neither design shows what happens after a person receives the peptide.
The laboratory studies identified CJC-1295 with DAC separately from related peptides and examined its breakdown products.
Mass spectrometry supported the identity of a 29-residue preparation without DAC. Other experiments tested its laboratory breakdown products and detection after known material was added to urine; they did not treat people with the fragment.
A change in hormone concentrations does not by itself establish better strength, body composition, injury recovery or long-term health. Those benefits, and any safety difference between the peptides, require trials that measure them directly.
The healthy-volunteer studies measured prolonged hormone effects. They did not establish improved recovery or long-term health, or better safety than modified GRF(1–29).
The reviewed sources did not establish a clinical benefit or a safety advantage. Direct human blood-concentration and hormone measurements for this peptide were also missing.
Teichman's abstract reported no serious adverse reactions in its two early trials. The more detailed FDA assessment (2024) identifies local reactions, flushing, headache, gastrointestinal symptoms, transient low blood pressure and increased heart rate across the available healthy volunteer studies. The FDA's current safety summary also identifies immune reaction, impurity and ingredient characterization concerns involving compounded CJC-1295.
The identification and laboratory detection studies did not administer modified GRF(1–29) to people, leaving its human harms poorly characterized. FDA also raises concerns about impurities, peptide aggregation and possible immune reactions in injectable preparations.
These are selected reports; several reports can come from one trial or cohort. Counts describe this library’s coverage.
No sections match this focus. Choose All sections to read the full comparison.
Read how the compounds differ, what direct studies found, and which questions remain open.
BPC-157 has been studied in several animal injury models and a few small human reports. Research on the defined acetylated TB-500 fragment is largely analytical or laboratory work. A small 2026 rat study tested BPC-157 alongside a TB-500-labeled preparation, but the paper did not fully identify that preparation or establish a clear difference between the two compounds.
CJC-1295 with DAC was designed to bind albumin and prolong growth-hormone signaling, and early studies measured its persistence and hormone effects in healthy volunteers. Modified GRF(1–29) shares the modified GHRH core but lacks that extension; most selected reports concern chemical identification, leaving much less human pharmacology to compare.
Direct trials found greater average weight and blood-glucose reductions with tirzepatide at the formulations tested. Receptor biology, available products, approved uses, cardiovascular outcomes and tolerability add context when comparing the two medicines.
Liraglutide and semaglutide activate the same GLP-1 receptor. Direct trials found larger average weight and blood-glucose reductions with semaglutide under the protocols tested. The comparison explains those trials, formulation differences, tolerability and separate cardiovascular evidence.
ACHIEVE-3 directly compared oral orforglipron capsules with oral semaglutide tablets in adults with type 2 diabetes taking metformin. Orforglipron lowered average blood glucose more. More participants reported stomach or intestinal adverse events or stopped treatment because of adverse events, and the average pulse increase was larger with orforglipron. The results concern the trial formulations and strengths; weight-management products need separate context.